The launch of a new product, especially one that represents a significant advancement like the iFuse Bedrock Granite Implant System, typically generates positive market sentiment. Completing inaugural surgeries demonstrates the product's viability and readiness for market, potentially leading to increased sales and market share for SI-BONE. This could positively impact SIBN's stock price in the short term as investors react to the company's growth prospects.